Guizhou Sanli Pharmaceutical Co Ltd

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

0.11

Vol. 1Y

—

Shs. 5Y

1.44%

Rev. 5Y

21.99%

Div Yld LY

—

Div Yld TTM

—

Revenues

1.70b

-20.59%

Net income

46m

-83.12%

CFO

165m

+53.71%

Dividend

Jun 30, 20260.06 /sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

This pharmaceutical enterprise is dedicated to the comprehensive process of developing, manufacturing, and distributing medicinal products. Its diverse portfolio includes therapeutic solutions for children, respiratory ailments, cardiovascular and cerebrovascular disorders, digestive issues, trauma recovery, rehabilitation needs, and ophthalmic conditions. The company commenced operations in 1995 and maintains its primary base in Guiyang, China.

URL

https://www.gz-sanli.com/

IPO date

Apr 28, 2020

Employees

Domiciled in

Incorporated in

Valuation

Latest on right Latest on left

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT